Nuvectra (NASDAQ:NVTR) Shares Down 14.8%

Nuvectra Corp (NASDAQ:NVTR)’s share price was down 14.8% on Thursday . The stock traded as low as $1.53 and last traded at $1.56, approximately 558,252 shares traded hands during trading. An increase of 40% from the average daily volume of 399,389 shares. The stock had previously closed at $1.83.

Several analysts have recently weighed in on NVTR shares. JMP Securities lowered their price objective on shares of Nuvectra to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Nuvectra from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Wednesday, July 10th. ValuEngine upgraded shares of Nuvectra from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Piper Jaffray Companies lowered their price objective on shares of Nuvectra from $18.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $8.75.

The company’s 50-day moving average price is $1.84 and its two-hundred day moving average price is $5.85. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.42 and a current ratio of 4.86. The stock has a market cap of $32.73 million, a PE ratio of -0.49 and a beta of 0.75.



Nuvectra (NASDAQ:NVTR) last issued its earnings results on Wednesday, July 31st. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The company had revenue of $12.35 million for the quarter, compared to analysts’ expectations of $12.42 million. Nuvectra had a negative net margin of 99.08% and a negative return on equity of 58.23%. Equities research analysts forecast that Nuvectra Corp will post -2.44 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. BNP Paribas Arbitrage SA purchased a new position in Nuvectra in the 1st quarter worth $40,000. Thompson Siegel & Walmsley LLC purchased a new position in Nuvectra in the 1st quarter worth $64,000. Acadian Asset Management LLC purchased a new position in Nuvectra in the 2nd quarter worth $35,000. SNS Financial Group LLC purchased a new position in Nuvectra in the 2nd quarter worth $36,000. Finally, Resources Investment Advisors LLC. purchased a new position in Nuvectra in the 2nd quarter worth $39,000. Institutional investors own 78.10% of the company’s stock.

About Nuvectra (NASDAQ:NVTR)

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

See Also: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.